Browse by Audience
Skip to content
Papers of the Week
Switching from ligand to receptor anti-calcitonin gene-related peptide (CGRP) antibodies or vice versa in non-responders: A controlled cohort study.
Authors
van Veelen N, van der Arend BWH, Hiele E, van Zwet EW, Terwindt GMAbstract
Limited options exist for migraine prevention after stopping anti-calcitonin gene-related peptide monoclonal antibodies. A systematic review examining the benefits of switching between different classes (ligand vs. receptor monoclonal antibody) is essential, alongside well-designed real-world studies.